Trial Profile
Phase II trial of chronic oral ZD 1839 (IRESSA) (NSC-715055) in both previously-untreated and previously-treated patients with selected stage IIIB and IV bronchioloalveolar carcinoma (BAC).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2023
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Adenocarcinoma; Bronchiolo-alveolar adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 17 Sep 2005 New trial record.